LAPS-Exendin4: Phase IIIb data

The double-blind, U.S. Phase IIIb Study HM-EXC-205 in 297 obese patients without diabetes showed that once-weekly 4 and 6 mg subcutaneous efpeglenatide in combination with a hypocaloric diet reduced b...